Our Latest
November 17, 2026PostNovember 17, 2026
Rat Models - Global Strategic Business Report 2026: Secure Share of a $2.9 Billion Market by 2032
B
BiotechNews.io4 min read
PostNovember 17, 2026
Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
B
BiotechNews.io4 min read
PostNovember 17, 2026
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
B
BiotechNews.io4 min read
Also on the bench
- BetterLife Pharma Announces Stock Option Grant
- BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity-Related Effects of Non-Hallucinogenic BETR-001 at Neuroscience 2026
- Senti Bio Announces Reverse Stock Split
- Thermosome Closes Exclusive Global Licensing Agreement with Avenor Therapeutics
- Mobile Apps for DNA Sequencing Market to Reach $2.4 Billion by 2031
- Kraig Biocraft Laboratories CEO Publishes Forbes Technology Council Article on the Future of Bio-Engineered Materials
- Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related Disease
- Burning Rock Announces 2026 Annual General Meeting to be Held on December 22, 2026
- CancerVax Successfully Kills Cancer Cells in Landmark Test
- New AI-Powered Canine DNA Technology Helps Dog Owners Understand Their Dogs' Lifetime Cancer and Heart Disease Risks
- IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
- Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
- Insight Molecular Diagnostics Announces Proposed Public Offering
- Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
- ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
- Exicure Announces Filing of Notification of Late Filing on Form 12b-25
- Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower – HBSS
View all Posts112 posts on Biotech News